Review · United States
Semaglutide
Reviewed on
Approval and product status
Yes. Some semaglutide prescription products are FDA-approved for specific uses
Ozempic, Rybelsus, and Wegovy are distinct approved products. Wegovy HD is a higher-dose Wegovy injection strength. Evidence for one product or form does not automatically apply to another.
What was measured in people?
- Health results · Strong
- Large studies support the approved uses listed on each product label.
- Body changes · Strong
- Studies have measured how approved products act in the body and how the body processes them.
A change in a hormone or body signal does not by itself prove a health benefit.
Important limits
This tool is not an independent medical review. It does not recommend treatment.
This guide does not recommend a product, say who can use it, or give dosing instructions. A licensed clinician must use the current label and a person's medical history to make treatment decisions.
Still unknown: A shared ingredient name does not make two products the same. Evidence from an approved product does not automatically apply to an unapproved, compounded, counterfeit, or research-labeled product. The name alone does not prove equal quality, safety, or results.
This record cannot check a package, seller, batch, or personal treatment. It does not provide sport clearance.
Approval fact checks
“Semaglutide is FDA-approved.”
Supported with scope. FDA approves a specific product for specific uses. The current Wegovy label lists different forms, groups of people, uses, and limits.
Applies to: The exact semaglutide products, forms, people, and uses named in current FDA labels.
Cited sources (3)
Products in this review
These are selected records, not every product or form.
Ozempic
- Ingredients and form
- Injection
- How it enters the body
- Injection under the skin
- Use and people covered
- Adults with type 2 diabetes for blood-sugar control. The label also covers heart-risk reduction in adults with type 2 diabetes and established heart disease. It covers kidney-risk reduction in adults with type 2 diabetes and chronic kidney disease.
Published label: May 2026
Read the published Ozempic FDA label (PDF)Rybelsus
- Ingredients and form
- Tablet
- How it enters the body
- Tablet by mouth
- Use and people covered
- Adults with type 2 diabetes for blood-sugar control. The label also covers heart-risk reduction in adults with type 2 diabetes who are at high risk. It is not approved for weight management.
Published label: October 2025
Read the published Rybelsus FDA label (PDF)Wegovy
- Ingredients and form
- Injection and tablet formulations
- How it enters the body
- Injection under the skin or tablet by mouth
- Use and people covered
- The injection label covers weight management in defined adults and children age 12 and older. It also covers heart-risk reduction in defined adults. MASH is a liver disease. When used with a reduced-calorie diet and increased physical activity, the injection label covers MASH in adults without cirrhosis who have moderate to advanced liver scarring (F2–F3). The tablet label covers adult weight management and heart-risk reduction.
Published label: June 2026
Read the published Wegovy FDA label (PDF)Wegovy HD
- Ingredients and form
- 7.2 mg injection strength
- How it enters the body
- Injection under the skin
- Use and people covered
- The 7.2 mg Wegovy injection strength for the adult weight-management group named in the label.
Published label: June 2026
Read the published Wegovy HD FDA label (PDF)What the research shows
FDA-reviewed semaglutide products have approved uses and official labels. Each label says who the product is for, its warnings, side effects, and directions. Read the current label for the exact product. Do not rely on the ingredient name alone.
Read all Semaglutide fact checksSources used in this review
A source may support some statements, not all of them. Use the links above or this review to see what each source supports.
Show 8 sources
- OZEMPIC (semaglutide) prescribing information, revised 05/2026
U.S. Food and Drug Administration · Drug label · 2026
Source accessed
- RYBELSUS (semaglutide) prescribing information, revised 10/2025
U.S. Food and Drug Administration · Drug label · 2025
Source accessed
- WEGOVY (semaglutide) prescribing information, revised 06/2026
U.S. Food and Drug Administration · Drug label · 2026
Source accessed
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss
U.S. Food and Drug Administration · Regulatory · 2026
Source accessed
- Drug approvals and databases
U.S. Food and Drug Administration · Regulatory · 2026
Source accessed
- Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
PubMed · Journal of Medicinal Chemistry · Preclinical · 2015
Source accessed
- FDA substance record: semaglutide identity (not an approval record)
U.S. Food and Drug Administration · Reference · 2026
Source accessed
- 2026 Monitoring Program
World Anti-Doping Agency · Anti-doping · 2026
Source accessed